Skip to main content

Directors' Report:
Our performance

Pipeline

Compound Mechanism Areas under investigation Phase Estimated filing date
NCEs I II III Europe US
AZD3355 inhibitor of transient lower oesophageal sphincter relaxations (TLESR) GERD selected selected 2011 2011
AZD2066 metabotropic glutamate receptors subtype 5 GERD selected
AZD1386 vanilloid receptor 1 antagonist GERD selected
 
Line extensions
Nexium proton pump inhibitor peptic ulcer bleeding selected selected selected 2Q 2008 2Q 2008
Nexium sachet formulation proton pump inhibitor GERD selected selected selected Approved1 Launched
Nexium low dose aspirin combination proton pump inhibitor low dose aspirin associated peptic ulcer selected selected selected 1H 2009
Nexium proton pump inhibitor extra-oesophageal reflux disease selected selected 2H 20092 2H 20092

1Approved by EU reference member state, mutual recognition procedure ongoing.

2Project Extraesophageal reflux disease (reflux asthma) will be completed but will not result in a regulatory filing.

For discontinued projects see the Development pipeline section.

Our pipeline includes life cycle management initiatives for approved products mentioned above, as well as development compounds. Our focus is on developing novel approaches to treating GERD by inhibition of reflux with or without concomitant treatment of gastro-oesophageal hypersensitivity. During 2007, AZD3355, which inhibits transient lower oesophageal sphincter relaxations, was tested in patients with GERD and showed positive effects in a phase IIa study. The development of AZD3355 in phase II is progressing.

Back to top ↑